-
2024-517816-31-00
4
2021-03-19
For patients with advanced/metastatic gastric adenocarcinomas in
progr
-
2024-514344-82-00
5
2021-02-18
patients with acute respiratory failure from undetermined etiology
-
2023-504403-92-00
1
2021-02-15
Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymp
-
2024-516111-25-00
5
2020-11-09
Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Per
-
2024-512050-13-00
5
2020-09-22
HER2-positive advanced breast cancer
-
2023-506435-15-00
3
2020-08-25
Prostate cancer
-
2024-515343-39-00
4
2020-08-14
Malignant Peritoneal Mesothelioma
-
2024-514471-18-00
5
2020-05-13
Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Mar
-
2023-504036-17-00
5
2020-05-07
Chronic Lymphocytic Leukemia (CLL)
-
2024-512734-15-00
1
2019-10-23
Non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
2024-515308-38-00
5
2019-09-21
Adults patients with isolated acute urticaria presenting to the emerge
-
2024-516201-23-00
4
2019-08-26
Lung Cancer, NSCLC
-
2024-514705-62-00
5
2019-07-08
Recurrent rectal cancer after local excision
-
2024-513374-22-00
5
2019-04-30
Short Bowel Syndrome
-
2023-508343-48-00
5
2019-01-25
Adult patients with relapsed or refractory aggressive B-cell non-Hodgk
-
2024-516416-22-00
10
2019-01-17
malignancy of thyroid nodules
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2022-502938-30-00
5
2018-12-10
Moderate and Severe Atopic Dermatitis
-
2024-519336-16-00
10
2018-10-31
Relapsed or Refractory Angioimmunoblastic T cell Lymphoma
-
2024-515051-38-00
5
2018-07-20
Non-small Cell Lung Cancer
-
2024-515356-21-00
5
2018-04-17
Adult subject (18 years of age older) with low or intermediate-1 IPSS
-
2024-516904-40-00
5
2018-03-27
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
-
2023-508757-75-00
5
2017-09-18
Stage IV Non-Small Cell Lung Cancer (NSCLC)
-
2022-501360-18-00
5
2017-03-15
Early Stage Non-Small Cell Lung Cancer (NSCLC)